Table 1.
Patient characteristics of the BoNT-A naive treatment (n = 11), BoNT-A naive untreated (n = 11) and BoNT-A not-naive treatment group (n = 15) at the time of the baseline assessment.
| Group | BoNT-A Naive Treatment | BoNT-A Naive Untreated | BoNT-A Not-Naive Treatment |
|---|---|---|---|
| Age (years) | 3.3 (1.2) | 2.8 (1.8) | 6.4 (2.5) |
| Topographic involvement | Bilateral, n = 7 Unilateral, n = 4 |
Bilateral, n = 4 Unilateral, n = 7 |
Bilateral, n = 8 Unilateral, n = 7 |
| Gender | Boy, n = 8 Girl, n = 3 |
Boy, n = 4 Girl, n = 7 |
Boy, n = 8 Girl, n = 7 |
| GMFCS level | I, n = 6 II, n = 1 III, n = 4 |
I, n = 6, II, n = 1 III, n = 4 |
I, n = 5 II, n = 8 III, n = 2 |
| Previous BoNT-A sessions | NA | NA | 1–2, n = 9 3–6, n = 6 |
| Time between two assessments (weeks) | 27.4 (3.4)/24–36 | 25 (2.5)/20–30 | 26.7 (3.6)/23–35 |
Age is presented as median (interquartile range). Time between assessments is presented as median (interquartile range)/minimum-maximum. BoNT-A, botulinum neurotoxin type-A; n, number, GMFCS, gross motor function classification system; NA, not applicable.